Riskpilot← Back to searchSign inGet full accessGLYCANOVA AS
ASActiveOrg 994035495Øraveien 2, 1630 Gamle FredrikstadManufacture of pharmaceutical preparations · NACE 2120Est. 20093 employees
Revenue 2024
NOK 1,4M
+39% vs 2023
EBITDA margin
-67.4%
+66% vs 2023
Equity ratio
-261.5%
Financial strength
Net profit 2024
NOK -1,1M
+63% vs 2023
| Revenue | NOK 1,4M | +39% |
| EBITDA | NOK -947K | +66% |
| Net profit | NOK -1,1M | +63% |
| Total assets | NOK 941K | +52% |
| Equity | NOK -2,5M | -8% |
| Employees | 3 | — |
Legal name
GLYCANOVA AS
Org number
994035495
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
30. april 2009
Share capital
NOK 409 943
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Daglig leder og styrets leder i fellesskap.
Company purpose
Produksjon og salg av matvareprodukter og farmasøytika.
Address
Øraveien 2, 1630 Gamle Fredrikstad
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 975 | 2 200 | 2 573 | 1 009 | 1 405 |
| Staff expenses | 3 501 | −1 992 | −3 046 | −1 110 | −1 483 |
| EBITDA | 4 499 | −2 412 | −3 525 | −2 756 | −947 |
| Depreciation & amort. | −150 | −353 | −353 | −167 | −105 |
| EBIT | 4 349 | −2 765 | −3 877 | −2 923 | −1 053 |
| Net financials | 11 | −70 | −20 | 14 | −10 |
| Profit before tax | 4 360 | −2 835 | −3 898 | −2 910 | −1 062 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 4 360 | −2 835 | −3 898 | −2 910 | −1 062 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 495 | 4 420 | 1 614 | 619 | 941 |
| Equity | −1 108 | 3 526 | −372 | −2 274 | −2 461 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 603 | 894 | 1 985 | 2 892 | 3 402 |
| Total debt | 3 603 | 894 | 1 985 | 2 892 | 3 402 |
EBITDA margin
-67.4%
This company
15.8%
Market median
-527% vs market
20202024
Equity ratio
-261.5%
This company
38.2%
Market median
-785% vs market
20202024
Return on equity
-106217100.0%
This company
18.4%
Market median
-577266948% vs market
20202024
Net profit margin
-75.6%
This company
8.1%
Market median
-1033% vs market
20202024
Asset turnover
1.49×
This company
1.12×
Market median
+33% vs market
20202024
Debt / equity
1.38×
This company
0.62×
Market median
-123% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LL Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Former (2) | ||
| Board of Directors | 2021 – 2021 | |
| Board of Directors | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 13.92% | 13.92% | 2024 | |
| Individual | 9.89% | 9.89% | 2024 | |
| Individual | 7.58% | 7.58% | 2024 | |
| Company | 6.69% | 6.69% | 2022 | |
| Company | 6.62% | 6.62% | 2024 | |
| Individual | 5.85% | 5.85% | 2024 | |
| Company | 5.73% | 5.73% | 2024 | |
| Individual | 5.1% | 5.1% | 2024 | |
| Company | 3.95% | 3.95% | 2024 | |
| Individual | 3.45% | 3.45% | 2024 | |
| Individual | 3.3% | 3.3% | 2024 | |
| Company | 3.02% | 3.02% | 2024 | |
| Company | 2.16% | 2.16% | 2024 | |
| Company | 1.78% | 1.78% | 2024 | |
Rais, Enrique | Company | 1.52% | 1.52% | 2024 |
| Individual | 1.5% | 1.5% | 2024 | |
| Individual | 1.27% | 1.27% | 2024 | |
| Company | 1.27% | 1.27% | 2024 | |
| Company | 1.12% | 1.12% | 2024 | |
| Individual | 1.02% | 1.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GLYCANOVA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lewis Linden Kristiansen | Chief Executive Officer | 0 companies |
| Dag Børge Hustad | Board of Directors | 0 companies |
| Terje Pedersen | Chairman | 0 companies |
| Geir Sand Nilsen | Board of Directors | 0 companies |
| Christian Peter Thorn Walter | Board of Directors | 0 companies |